CITF Research Results

CITF Research Results2023-10-27T10:53:53-04:00

Fourth dose of the COVID-19 vaccine is highly immunogenic and safe in people who have received an allogeneic hematopoietic stem cell transplant

A CITF-funded study, published in Transplantation and Cellular Therapy, found that a fourth dose of the COVID-19 vaccine is highly immunogenic (induces a good immune response) and safe in people who have a received an allogeneic Hematopoietic Stem Cell Transplant (HSCT).

September 1, 2023|Higher risk due to health conditions|

CITF-funded findings on seroprevalence and effects of COVID-19 on children and adolescents

Ongoing monitoring of the serological status of children is important, particularly in the context of new variants of concern, low vaccine coverage, and low uptake of testing. Here, members of the CITF Secretariat summarize results from the four presentations given during the breakout session, “Seroprevalence and effects of COVID-19 on children and adolescents,” at the CITF Scientific Meeting in Vancouver, March 8-10, 2023.

August 21, 2023|Pediatrics|

Respiratory syncytial virus antibody functions diminished during peak of COVID-19 pandemic, causing more severe RSV infections

A CITF-funded study, published in preprint and not-yet peer-reviewed, found that the almost complete absence of RSV circulation during the peak of COVID-19 pandemic mitigation measures led to waning antibody-mediated and cellular responses that protect against severe respiratory syncytial virus (RSV) infection.

August 21, 2023|Pediatrics|

Predictors of Post COVID-19 Condition

A CITF-funded study, published in preprint and not yet peer-reviewed, found positive associations between Post COVID-19 Condition (PCC), also known as Long COVID, and anti-spike (S), and anti-receptor binding domain (RBD) IgG titres, which were not statistically significant.

August 21, 2023|Long COVID|
Go to Top